Literature DB >> 3051283

Effects of D-penicillamine on mononuclear cells in vitro.

J L Riestra1, M Harth, A Rodriguez, C L Larrea.   

Abstract

D-penicillamine (D-pen) inhibited pokeweed mitogen-induced plaque-forming cell (PFC) response in a dose-dependent manner. This inhibition was irreversible as preincubation for a few hours with the drug followed by washes still caused suppression of the PFC response. Pretreatment of the different mononuclear cell populations with D-pen for short periods (2-24 h) showed that both macrophages (Mo) and B lymphocytes were affected by the drug. By contrast T cells were resistant. Mo appears to be more susceptible to D-pen than B cells, and in the case of drug-treated Mo, the response was restored completely with the addition of 20% fresh Mo. Our results show that D-pen, without exogenous Cu2+, inhibits the polyclonal immunoglobulin secretion by human mononuclear cells in vitro due to a strong effect on both Mo and B cells. This may explain the decrease in serum immunoglobulin levels seen in patients with rheumatoid arthritis undergoing this therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3051283     DOI: 10.1007/BF00272433

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  29 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Inhibition of T cell-dependent antibody production by D-penicillamine. Different requirements for Cu2+ in suppression of polyclonal and antigen-specific B cell responses.

Authors:  J Petersen
Journal:  Allergy       Date:  1987-01       Impact factor: 13.146

3.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

4.  Pharmacokinetics of reduced D-penicillamine in patients with rheumatoid arthritis.

Authors:  M Butler; G Carruthers; M Harth; D Freeman; J Percy; D Rabenstein
Journal:  Arthritis Rheum       Date:  1982-01

5.  Collagen cross-linking. Effect of D-penicillamine on cross-linking in vitro.

Authors:  R C Siegel
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

6.  Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen.

Authors:  A J Dixon; J Davies; T L Dormandy; E B Hamilton; P J Holt; R M Mason; M Thompson; J C Weber; D W Zutshi
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

7.  Specific sensitization of Lyt-1+2- T cells to spleen cells modified by the drug D-penicillamine or a stereoisomer.

Authors:  N Nagata; U Hurtenbach; E Gleichmann
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

Review 8.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

9.  Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester.

Authors:  D L Thiele; M Kurosaka; P E Lipsky
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

10.  Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes.

Authors:  P E Lipsky
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

View more
  1 in total

Review 1.  Slow-acting antirheumatic drugs. Drug interactions of clinical significance.

Authors:  R A Munro; R D Sturrock
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.